000283101 001__ 283101
000283101 005__ 20251230150232.0
000283101 0247_ $$2doi$$a10.3390/diagnostics15243132
000283101 0247_ $$2pmid$$apmid:41464133
000283101 037__ $$aDZNE-2025-01508
000283101 041__ $$aEnglish
000283101 082__ $$a610
000283101 1001_ $$00000-0002-9534-2374$$aSperber, Pia Sophie$$b0
000283101 245__ $$aAnti-NMDA-Receptor GluN1 Antibody Serostatus Is Robust in Acute Severe Stroke.
000283101 260__ $$aBasel$$bMDPI$$c2025
000283101 3367_ $$2DRIVER$$aarticle
000283101 3367_ $$2DataCite$$aOutput Types/Journal article
000283101 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767103300_6287
000283101 3367_ $$2BibTeX$$aARTICLE
000283101 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283101 3367_ $$00$$2EndNote$$aJournal Article
000283101 520__ $$aBackground: Anti-N-methyl-D-aspartate IgM and IgA antibodies (NMDAR1-abs) are associated with unfavorable stroke outcomes and may be risk factors thereof. However, to utilize NMDAR1-abs serostatus for risk assessment in acute stroke, it is crucial to understand the robustness of serostatus during this phase. Therefore, we investigated the robustness of NMDAR1-abs serostatus and titer levels up to seven days after stroke. Methods: In this exploratory analysis of the multicenter STRAWINSKI trial (identifier: NCT01264549), patients with severe ischemic stroke (NIHSS ≥ 9) in the middle cerebral artery territory were included. The first blood sample was taken within 36 h and then daily from day two to seven after stroke. NMDAR1-abs immunoglobulin (Ig)A and IgM were assessed in serum using cell-based assays. We initially measured NMDAR1-abs in the total cohort on day 1. Subsequently, in samples from seropositive and matched seronegative patients, we measured NMDAR1-abs on each following day. Titer dilutions started from 1:10 up to 1:1000. Seropositivity was defined as any titer > 0. Results: Out of 171 patients (mean age = 76 [SD = 11], median NIHSS = 15 [IQR = 12-18]), 16 (9%) individuals were seropositive. Seropositive patients remained seropositive and matched seronegative participants remained seronegative over sequential measurements. Although titer levels remained largely unchanged, some patients showed fluctuating titers. Conclusions: The status of NMDAR1-abs seropositivity is stable during acute stroke, with little to no variation in titer levels.
000283101 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283101 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283101 650_7 $$2Other$$aNMDA-receptor
000283101 650_7 $$2Other$$aantibodies
000283101 650_7 $$2Other$$abiomarker
000283101 650_7 $$2Other$$astroke
000283101 7001_ $$aHotter, Benjamin$$b1
000283101 7001_ $$0P:(DE-2719)2811033$$aEndres, Matthias$$b2$$udzne
000283101 7001_ $$0P:(DE-2719)2810931$$aPrüss, Harald$$b3
000283101 7001_ $$00000-0001-7233-5342$$aMeisel, Andreas$$b4
000283101 770__ $$aDiagnostic, Predictive and Prognostic Biomarkers for Neurodegenerative Diseases
000283101 773__ $$0PERI:(DE-600)2662336-5$$a10.3390/diagnostics15243132$$gVol. 15, no. 24, p. 3132 -$$n24$$p3132$$tDiagnostics$$v15$$x2075-4418$$y2025
000283101 8564_ $$uhttps://pub.dzne.de/record/283101/files/DZNE-2025-1508_SUPP.zip
000283101 8564_ $$uhttps://pub.dzne.de/record/283101/files/DZNE-2025-1508.pdf$$yRestricted
000283101 8564_ $$uhttps://pub.dzne.de/record/283101/files/DZNE-2025-1508.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283101 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811033$$aExternal Institute$$b2$$kExtern
000283101 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000283101 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283101 9141_ $$y2025
000283101 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIAGNOSTICS : 2022$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-29T10:48:13Z
000283101 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-29T10:48:13Z
000283101 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-29T10:48:13Z
000283101 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-08-29T10:48:13Z
000283101 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
000283101 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
000283101 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000283101 980__ $$ajournal
000283101 980__ $$aEDITORS
000283101 980__ $$aVDBINPRINT
000283101 980__ $$aI:(DE-2719)1810003
000283101 980__ $$aUNRESTRICTED